Pearl seeks partner for COPD LAMA after positive Phase IIb results
This article was originally published in Scrip
Executive Summary
Pearl Therapeutics is planning Phase III trials of its lead fixed-dose combination bronchodilator product candidate, PT003, next year in chronic obstructive pulmonary disease (COPD) after reporting positive top-line Phase IIb results for glycopyrrolate, one of the individual components that make up PT003.